Urocap

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Urocap

Property Description
Active ingredient Tamsulosin Hydrochloride
Form Oral Capsule, Extended-Release
Pharmacological class Alpha-1 Adrenergic Receptor Antagonist
Common use Improving flow and relieving urinary symptoms
Origin Synthetic Small Molecule

What is the Active Ingredient and Class of Urocap?

Urocap is a prescription-only medicinal product containing the active ingredient Tamsulosin Hydrochloride. This compound is scientifically classified as an Alpha-1 Adrenergic Receptor Antagonist, often referred to as an alpha-blocker. A key characteristic of this synthetic small molecule is its high degree of functional selectivity for the alpha1A and alpha1D receptor subtypes. The drug is clinically recognized for its targeted effect on the lower urinary tract, distinguishing its primary pharmacological focus from less selective alpha-blockers. The active ingredient's profile is consistent with its intended site of action.


What is the General Purpose and Form of the Medicine?

The general purpose of Urocap is to improve the flow of urine and alleviate common urinary issues related to obstruction, a typical scenario for adult male patients. The medication is presented as an oral capsule or an extended-release capsule (controlled-release tablet), administered via the oral route. The controlled-release design is integral to the product's identity, as it ensures the Tamsulosin Hydrochloride is delivered slowly and steadily. This specific formulation is intended to maintain a consistent therapeutic effect over a 24-hour period with a single daily intake, making the management of urinary issues predictable.


How Does Urocap Generally Function to Improve Urine Flow?

Urocap generally functions by causing the relaxation of smooth muscle tissue located specifically in the prostate gland and the neck of the bladder. This mechanism occurs because the drug blocks the specific chemical signals that instruct these particular muscles to contract and tighten. By physically reducing the tension in these key areas, Urocap decreases the resistance to the passage of urine. This physiological action directly assists in reducing the difficulty and discomfort associated with a weak or obstructed urinary stream.

Regulatory References

  1. FDA Label on DailyMed (NIH/NLM)

What side effects are possible with Urocap?

Possible side effects and safety information

The safety profile for Urocap, containing Tamsulosin Hydrochloride, is defined by regulatory documents that classify potential adverse reactions based on their incidence and physiological system affected.

Frequency-Classified Adverse Reactions

The official classifications define the likelihood of occurrence:

  • Common (may affect up to 1 in 10 people): Reactions include dizziness, headache, and abnormal ejaculation (such as retrograde ejaculation or ejaculation failure).
  • Uncommon (may affect up to 1 in 100 people): Includes orthostatic hypotension (a drop in blood pressure upon standing), palpitations, and skin reactions like rash, pruritus, or urticaria.
  • Rare (may affect up to 1 in 1,000 people): Includes syncope (fainting) and angioedema (swelling of the face or throat).
  • Very Rare (may affect up to 1 in 10,000 people): Includes priapism (prolonged, painful erection) and Stevens-Johnson syndrome (a severe skin disorder).

Serious Adverse Reactions and Safety Constraints

Specific serious adverse reactions are documented, including those listed as Rare or Very Rare. In addition, the medicine has been associated with Intraoperative Floppy Iris Syndrome (IFIS), a complication observed during cataract or glaucoma surgery.

Safety limitations explicitly stated in official labeling include:

  • Contraindications: Urocap is contraindicated in individuals with a known history of orthostatic hypotension or severe hepatic insufficiency.
  • Exposure Patterns: Symptoms related to postural hypotension are noted to occur more frequently at the beginning of treatment.
  • Population Note: The medicine is not indicated for use in women or the pediatric population, and patients require screening for prostate cancer prior to and during treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that an overdose of Urocap (Tamsulosin Hydrochloride) is primarily characterized by the development of severe hypotensive effects. This acute hypotension may result in a critical drop in systolic blood pressure, with documented cases reporting levels as low as 70 mm Hg, potentially leading to syncope. Other documented manifestations of an overdose include vomiting and diarrhoea.

Required Emergency Actions

Should signs of severe hypotension occur, emergency medical attention must be sought immediately to provide cardiovascular support. The initial mandated action involves lying the patient down (supine position) to attempt blood pressure restoration. If this measure is insufficient, the official label mandates the use of volume expanders and, if necessary, vasopressors to manage the hypotension.

To impede further absorption, procedures such as gastric lavage may be performed, and activated charcoal along with an osmotic laxative may be administered. Renal function should be monitored as part of the general supportive measures. It is officially noted that dialysis is unlikely to be of help in managing an overdose due to the drug's very high plasma protein binding.

Therapeutic Uses of Urocap

Urocap is commonly used to provide supportive relief for symptoms across two major clinical domains: chronic urinary difficulty and acute stone passage. It is applied in contexts where additional management of discomfort is required to ease symptom distress.

The medication is relevant in clinical settings marked by recurrent symptoms associated with Benign Prostatic Hyperplasia (BPH) and is also considered relevant in situations where patients experience symptoms related to the passage of ureteral calculi (kidney stones).

It is generally used to help with conditions characterized by periods of heightened symptoms by assisting in addressing symptom clusters that interfere with daily functioning. This includes obstructive symptoms like urinary hesitancy and a weak stream, as well as irritative symptoms such as frequency, urgency, and nocturia. The therapeutic benefit helps support day-to-day comfort.

The medication is applied to provide supportive relief for symptoms that create noticeable physiological strain, assisting patients to cope more steadily with these difficult episodes.


Quick Fact: Supportive Relief for Voiding and Storage Symptoms

Urocap offers symptomatic relief that may assist patients with maintaining a sense of stability when symptoms are more noticeable during phases of increased distress, particularly by helping to reduce the overall symptom burden of prostate-related voiding and storage issues.

Regulatory References

  1. NIH MedlinePlus overview of Tamsulosin

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Urocap — Official Regulatory Information

The eligibility profile for Urocap (often Ursodeoxycholic Acid, UDCA, in regulatory documents) is defined by a set of absolute contraindications and specific population restrictions based on authoritative government sources.

Contraindications and Prohibited Use

Urocap is contraindicated and must not be used in patients with a documented hypersensitivity to bile acids (such as UDCA) or any excipients in the formulation. Use is also strictly prohibited in patients with certain conditions, including:

  • Calcified (radio-opaque) gallstones.
  • Acute inflammation of the gallbladder or biliary tract.
  • Biliary tract occlusion (blockage of the common bile duct or cystic duct).
  • Non-functioning gallbladder.
  • Severe hepatic insufficiency.

Age and Special Population Eligibility

  • Pregnancy and Lactation: Urocap is generally not recommended during pregnancy, especially the first trimester, and women of childbearing potential should use reliable contraception during treatment. Use during breastfeeding is also not recommended, as it is unknown if the drug passes into breast milk.
  • Pediatric Population: Use is typically not established or not recommended in children under 6 years of age. For children aged 6 to less than 18, use is sometimes approved only for specific, limited indications (e.g., liver disease associated with cystic fibrosis).
  • Organ Function: No dose adjustment is usually required for mild to moderate hepatic or renal impairment, but caution is advised, and regular liver function monitoring is mandated.

What should I know about interactions with other medicines?

Urocap Interactions with other medicines and products

Urocap (alfuzosin hydrochloride) can interact with several medicinal product categories, which may affect its safety and effectiveness. These interactions are primarily based on two mechanisms: its metabolism by the CYP3A4 enzyme in the liver and its activity as an alpha-adrenergic antagonist.

Interaction Type Interacting Products/Categories Interaction Effect Classification
Pharmacokinetic Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) Significantly increased alfuzosin blood levels, raising the risk of serious side effects. Contraindicated
Pharmacodynamic Other alpha-adrenergic antagonists Additive blood pressure-lowering effects, increasing risk of hypotension. Should not be used
Pharmacodynamic Antihypertensive medications (for high blood pressure) and Nitrates Increased risk of low blood pressure (hypotension) and fainting (syncope). Use with Caution
Pharmacodynamic Phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) Potential for marked symptomatic hypotension. Use with Caution
Pharmacodynamic Medications that prolong the QT interval Potential for increased risk of a rare heart rhythm abnormality. Use with Caution

Additionally, alfuzosin blood levels are significantly increased in patients with moderate or severe liver impairment (Childs-Pugh categories B and C), and its use is therefore contraindicated in this population. Patients should inform their healthcare provider of all medicines, supplements, and health conditions before starting Urocap.

Mechanism of Action

The mechanism of Urocap (Tamsulosin Hydrochloride) involves the specific targeting of Alpha-1 adrenergic receptors (alpha1) located in the smooth muscle of the lower urinary tract. The drug acts as a competitive antagonist with high functional selectivity for the alpha1A and alpha1D receptor subtypes, which are dense in the prostate capsule and bladder neck. By binding to these receptors, Urocap prevents the activation by the neurotransmitter Norepinephrine, inhibiting the alpha1-mediated signaling cascade that normally induces smooth muscle cell contraction.

The molecular blockade prevents the rise of intracellular calcium necessary for contraction, resulting in the physiological relaxation of the smooth muscle in these tissues. This action decreases the dynamic urethral resistance component mediated by muscle tone, as the mechanism operates solely on tone and not on the reduction of physical prostatic volume. The extended-release formulation provides sustained receptor occupancy to achieve the continuous inhibition of sympathetic tone over a 24-hour period.

Dosage and Administration Information

Urocap, which contains tamsulosin hydrochloride, is indicated for oral administration only, typically presented as a 0.4 mg extended-release capsule or prolonged-release tablet. To ensure the intended gradual release of the active ingredient over 24 hours, the dosage form must be swallowed whole and is strictly not to be crushed, chewed, or opened.


The standardized regimen for use begins with a dose of 0.4 mg taken once daily. This fixed daily schedule is intended to maintain a consistent therapeutic concentration. For adult patients who do not achieve an adequate response after 2 to 4 weeks of therapy, the dose may be titrated upward to a maximum of 0.8 mg once daily. If use is interrupted for several days, guidelines specify that therapy must be re-initiated with the 0.4 mg once-daily dose.


The instructions regarding the timing of administration relative to meals can differ based on the specific formulation. Certain regimens specify taking the capsule approximately one-half hour following the same meal each day. However, other prolonged-release tablet formulations may be designated to be taken independently of food. Furthermore, the medicine is not indicated for use in the pediatric population, and no specific dose adjustment is typically mandated for adult patients with mild to moderate renal or hepatic impairment.

Recent Clinical Evidence

Urocap, a capsule formulation containing tamsulosin (an alpha-1A adrenergic receptor antagonist) and dutasteride (a 5-alpha reductase inhibitor), has been the subject of clinical research, primarily focusing on its efficacy and safety in treating moderate-to-severe Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH).

Combination Therapy Efficacy

Long-term clinical trials lasting up to four years have investigated the combination of dutasteride and tamsulosin. The primary findings support the use of combination therapy for patients with enlarged prostates who are at a greater risk of disease progression. These studies demonstrated that the combination was superior to either monotherapy (dutasteride or tamsulosin alone) in two key areas:

  • Symptom Improvement: Combination therapy led to significantly greater and sustained improvement in overall LUTS, as measured by the International Prostate Symptom Score (IPSS), compared to tamsulosin alone.
  • Risk Reduction: The combination treatment showed a substantial reduction in the risk of Acute Urinary Retention (AUR) and the need for BPH-related surgery over the long term, which is a known benefit of the 5-alpha reductase inhibitor component.

Safety Profile and Considerations

Clinical data indicates that the overall safety profile of the combination is acceptable. However, the incidence of certain drug-related adverse events, such as impotence, decreased libido, and ejaculation disorders, was observed to be higher in patients receiving the combination compared to those on tamsulosin monotherapy. Other common side effects included dizziness. Physicians consider these trade-offs, along with the patient’s clinical profile, when prescribing the combined treatment. In general, starting combination therapy early, before signs of significant disease progression, has been shown to be more effective in reducing the long-term risk of AUR and BPH-related surgical intervention.

Frequently Asked Questions (FAQ)

Common questions about Urocap (FAQ)


Q: Is Urocap safe to use long-term?

Official documents indicate that for conditions like Benign Prostatic Hyperplasia (BPH), therapy may be continued long-term. The duration of use is not fixed and is determined by the condition being managed. Clinical management for long-term conditions often involves regular monitoring and assessment by a healthcare provider to ensure the continued appropriateness of the treatment.


Q: Can Urocap be used by older adults?

Studies have examined the use of this medicine in older patients and have not found overall differences in effectiveness compared to younger adults. However, regulatory guidance suggests that a greater sensitivity to the effects of the medicine in some older individuals cannot be ruled out.


Q: What is the difference between the brand-name Urocap and its generic version?

The brand-name product and its generic version both contain the exact same active ingredient, Tamsulosin Hydrochloride, and are required to meet the same regulatory standards for quality and performance. They are considered therapeutically equivalent. Any differences that exist would typically be in the inactive ingredients or the appearance of the capsule.


Q: How long does it usually take to notice if Urocap is working?

Although the medicine is designed to provide sustained action, the full extent of symptom improvement may not be fully noticeable for up to 4 weeks of regular dosing. Official prescribing information states that the dose may be adjusted if an adequate response is not achieved after this initial period.


Q: Is Urocap used for any other reason besides what is listed on the label?

According to official regulatory documents, the sole approved indication for this medicine is the treatment of the signs and symptoms of Benign Prostatic Hyperplasia (BPH). The medicine's official use is strictly defined by its approved regulatory label.


Q: What happens if I miss a dose of Urocap?

Official guidance regarding a missed dose provides specific steps for managing the interruption, based on the timeframe in which the dose is remembered. These instructions specify that taking two doses at once to compensate for a missed dose is not advised. The full set of instructions is described in the product information.


Q: Is it common to feel tired when starting Urocap?

Feelings of tiredness, weakness, or loss of energy are listed among the possible side effects reported in official documents. Dizziness is also a commonly reported reaction, particularly when first starting treatment.


Q: Can Urocap affect my sleep?

Official product information lists that difficulty falling asleep or staying asleep, sometimes referred to as insomnia, is a reported possible side effect of the medicine.


Q: Does Urocap interact with everyday vitamins or supplements?

While specific interactions with all vitamins and supplements are not detailed in the core regulatory label, there is a general caution regarding potential effects on the drug's metabolism. Official regulatory guidance emphasizes the importance of a healthcare provider being informed of all herbal remedies, vitamins, or nutritional supplements being taken.


Q: How long does Urocap stay in the body after the last dose?

Pharmacokinetic studies indicate that the active ingredient, Tamsulosin, has an apparent elimination half-life of approximately 14 to 15 hours in the target population. This half-life refers to the time it takes for the concentration of the drug in the bloodstream to decrease by half.


Q: Can Urocap cause problems with blurred vision?

Official documents indicate that blurred vision is listed as a possible side effect. The medicine has also been associated with a specific complication called Intraoperative Floppy Iris Syndrome (IFIS) that has been reported during cataract or glaucoma surgery.


Q: What should I do if I feel dizzy after taking Urocap?

Regulatory guidance notes that lightheadedness or dizziness is a common effect, particularly when moving suddenly from a seated or lying position. The prescribing information describes the physical maneuver of getting up slowly from a sitting or lying position as a way to potentially help reduce the risk of this specific side effect.


Q: Are there any specific foods or drinks that should be avoided while taking Urocap?

Official product information specifies that the capsule should be taken following the same meal each day. Furthermore, some regulatory information notes a potential for interaction, leading to a suggestion that the consumption of alcohol and grapefruit products be limited during the course of treatment.


Q: If I stop taking Urocap, do the effects wear off immediately?

The effects do not wear off immediately due to the sustained-release formulation and the active ingredient's half-life of 14 to 15 hours. This means that the drug concentration decreases gradually over time, and symptoms may slowly return after the medicine is stopped.


Q: Does Urocap interact with any common cold and flu medicines?

Official documents indicate there is a potential for interaction with certain over-the-counter cold and flu medicines. Specifically, products containing decongestants or strong inhibitors of the CYP3A4 enzyme may affect the drug's metabolism or its effect on blood pressure.


Q: Is the active ingredient in Urocap available as a generic drug?

The active ingredient, Tamsulosin Hydrochloride, is widely available in a generic formulation. Generic products must demonstrate bioequivalence and meet the same strict regulatory standards as the original brand-name medicine.


Q: What if I accidentally take two Urocap pills at once?

Taking more than the prescribed amount can lead to a sudden and significant drop in blood pressure, potentially causing an increased heart rate. Official guidance states that a healthcare provider must be informed immediately for evaluation of the situation.


Q: Why does my doctor call Urocap by a different name?

Healthcare providers may use the name of the active ingredient, Tamsulosin Hydrochloride, instead of the brand name, as is common practice. Additionally, the same active ingredient may be sold under various other brand names across different regions.


Q: Can Urocap cause stomach upset or nausea?

Nausea, diarrhea, or general stomach upset are listed among the possible reported side effects in the official product information.


Q: Are there any non-drug treatments that are often used with Urocap?

Official health guidance for the management of the underlying condition often describes non-drug approaches alongside medication. These approaches include lifestyle changes such as fluid management and specific dietary adjustments, including increasing fiber intake.


Q: Does Urocap affect laboratory blood tests?

The prescribing information states that a screening process for prostate cancer must be performed before and during treatment, which typically involves blood tests (e.g., PSA levels). The treatment regimen includes this specific monitoring requirement.


Q: Does Urocap have any potential for misuse or dependence?

The active ingredient in this medicine, Tamsulosin, is not classified as a controlled substance by regulatory bodies in the United States. This classification indicates that the medicine has no recognized potential for misuse or dependence.


How should Urocap be stored and disposed of?

Urocap (tamsulosin hydrochloride capsules) must be stored according to specific regulatory requirements to maintain its stability and effectiveness.

Storage Conditions

The capsules must be kept at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). It is essential to keep the medicine from freezing and away from excess heat and excess moisture.

For container requirements, Urocap must be stored in the original container and the container must be tightly closed. Crucially, the medication must be kept out of the sight and reach of children.

Disposal Instructions

Any unused or outdated medicine must be disposed of properly. Disposal of Urocap must be done in accordance with local regulations for pharmaceutical waste and should not be released into the environment or flushed down drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Urocap found in:

A-Z Index: